Melissa Lamar1, Lei Yu2, Leah H Rubin3, Bryan D James4, Lisa L Barnes5, Jose Marcelo Farfel6, Chris Gaiteri2, Aron S Buchman2, David A Bennett2, Julie A Schneider7. 1. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA. Electronic address: melissa_lamar@rush.edu. 2. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. 3. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA. 5. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. 6. Department of Geriatrics, University of Sao Paulo Medical School, Sao Paulo, Brazil. 7. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA; Department of Pathology, Rush University Medical Center, Chicago, IL, USA.
Abstract
INTRODUCTION: Apolipoprotein E (APOE) is a susceptibility gene for late-onset Alzheimer's disease neuropathology; less is known about the relationship between APOE and cerebrovascular disease (CVD) neuropathology. METHODS: We investigated associations of APOE status with arteriolosclerosis, macroinfarcts and microinfarcts, and atherosclerosis in 1383 adults (65.9-108.2 years at death) with and without dementia. Excluding ε2/ε4 carriers, multivariable regressions for each CVD-related neuropathology compared ε4 and ε2 carriers to ε3/ε3 carriers adjusting for confounders including age and Alzheimer's neuropathology. RESULTS: Three hundred forty-two individuals (24.7%; ∼87.7 years at death; 39.9% nondemented) were ε3/ε4 or ε4/ε4, and 180 (13.0%; ∼89.9 years at death; 66.6% nondemented) were ε2/ε3 or ε2/ε2. ε4 carriers had higher odds of macroinfarcts (odds ratio = 1.41, 95% confidence interval: 1.02-1.94, P = .03), whereas ε2 carriers had higher odds of moderate-to-severe arteriolosclerosis (odds ratio = 1.68, 95% confidence interval: 1.15-2.45, P = .006) compared to ε3/ε3 carriers. Age-stratified analyses suggested that these relationships were driven by ε4 carriers <90 years at death and ε2 carriers ≥90 years at death, respectively. DISCUSSION: APOE differentially affects type and timing of CVD-related neuropathology.
INTRODUCTION:Apolipoprotein E (APOE) is a susceptibility gene for late-onset Alzheimer's disease neuropathology; less is known about the relationship between APOE and cerebrovascular disease (CVD) neuropathology. METHODS: We investigated associations of APOE status with arteriolosclerosis, macroinfarcts and microinfarcts, and atherosclerosis in 1383 adults (65.9-108.2 years at death) with and without dementia. Excluding ε2/ε4 carriers, multivariable regressions for each CVD-related neuropathology compared ε4 and ε2 carriers to ε3/ε3 carriers adjusting for confounders including age and Alzheimer's neuropathology. RESULTS: Three hundred forty-two individuals (24.7%; ∼87.7 years at death; 39.9% nondemented) were ε3/ε4 or ε4/ε4, and 180 (13.0%; ∼89.9 years at death; 66.6% nondemented) were ε2/ε3 or ε2/ε2. ε4 carriers had higher odds of macroinfarcts (odds ratio = 1.41, 95% confidence interval: 1.02-1.94, P = .03), whereas ε2 carriers had higher odds of moderate-to-severe arteriolosclerosis (odds ratio = 1.68, 95% confidence interval: 1.15-2.45, P = .006) compared to ε3/ε3 carriers. Age-stratified analyses suggested that these relationships were driven by ε4 carriers <90 years at death and ε2 carriers ≥90 years at death, respectively. DISCUSSION: APOE differentially affects type and timing of CVD-related neuropathology.
Authors: H C O'Donnell; J Rosand; K A Knudsen; K L Furie; A Z Segal; R I Chiu; D Ikeda; S M Greenberg Journal: N Engl J Med Date: 2000-01-27 Impact factor: 91.245
Authors: Lisa L Barnes; Raj C Shah; Neelum T Aggarwal; David A Bennett; Julie A Schneider Journal: Curr Alzheimer Res Date: 2012-07 Impact factor: 3.498
Authors: Eseosa T Ighodaro; Erin L Abner; David W Fardo; Ai-Ling Lin; Yuriko Katsumata; Frederick A Schmitt; Richard J Kryscio; Gregory A Jicha; Janna H Neltner; Sarah E Monsell; Walter A Kukull; Debra K Moser; Frank Appiah; Adam D Bachstetter; Linda J Van Eldik; Peter T Nelson Journal: J Cereb Blood Flow Metab Date: 2016-01-06 Impact factor: 6.200
Authors: C Bétard; Y Robitaille; M Gee; D Tiberghien; D Larrivée; P Roy; J A Mortimer; D Gauvreau Journal: Neuroreport Date: 1994-10-03 Impact factor: 1.837
Authors: Riki E Slayday; Daniel E Gustavson; Jeremy A Elman; Asad Beck; Linda K McEvoy; Xin M Tu; Bin Fang; Richard L Hauger; Michael J Lyons; Ruth E McKenzie; Mark E Sanderson-Cimino; Hong Xian; William S Kremen; Carol E Franz Journal: J Int Neuropsychol Soc Date: 2020-07-14 Impact factor: 2.892
Authors: Michael Tran Duong; Ilya M Nasrallah; David A Wolk; Catherine C Y Chang; Ta-Yuan Chang Journal: Front Aging Neurosci Date: 2021-03-25 Impact factor: 5.750
Authors: Sonal Agrawal; Lei Yu; Alifiya Kapasi; Bryan D James; Konstantinos Arfanakis; Lisa L Barnes; David A Bennett; Sukriti Nag; Julie A Schneider Journal: Brain Pathol Date: 2021-02-23 Impact factor: 6.508